Sex-difference of multifactorial intervention on cardiovascular and mortality risk in DKD: post-hoc analysis of a randomised clinical trial
Authors' conclusion
MT similarly reduces the risk of MACEs in either sex. This therapeutic approach is associated with a survival advantage in women as compared with men and it may represent an important rationale to motivate physicians in overcoming their therapeutic inertia often encountered in female patients as well as to encourage patients of both sexes at improving their adherence to multidrug therapy.
Study context
- Population
- Patients with T2D and DKD; women (104 multifactorial therapy (MT), 105 Usual Care (UC)) and men (103 MT, 83 UC)
- Comparison
- Intensive multifactorial therapy vs usual care, in women and in men
- Primary endpoint
- Occurrence of MACEs
- Follow-up
- Median 13.0 years
Methodological detailsopen-label, cluster randomized, stratified by sex
- Open-label
- Cluster randomized
- Stratified by sex
Primary result
As reported in the abstract
MACE risk reduction with MT vs UC, by sex · median follow-up 13.0 years
MACE risk reduction with MT vs UC in women
52%
MACE risk reduction with MT vs UC in men
44%
Secondary outcomes
| Outcome | P value |
|---|---|
| All-cause death risk reduction with MT vs UC, by sex · median follow-up 13.0 yearsReduction greater in women (44% vs 12%) | P = 0.019 |
- All-cause death risk reduction with MT vs UC, by sex — Mortality risk reduction with MT in women
- 44%
- All-cause death risk reduction with MT vs UC, by sex — Mortality risk reduction with MT in men
- 12%
Events recorded · median follow-up 13.0 years
- MACE (48.5% in women)
- 262
- Deaths (53.6% in women)
- 189
Achieving ≥3 therapeutic targets
- Women in MT
- 44%
- Men in MT
- 47%
- Women in UC
- 16%
- Men in UC
- 20%
- Achievement of therapeutic goals similar by sex
Original publication
Sex-difference of multifactorial intervention on cardiovascular and mortality risk in DKD: post-hoc analysis of a randomised clinical trial. Cardiovasc Diabetol. Published 5 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →